Kestra Medical Technologies (NASDAQ:KMTS) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded Kestra Medical Technologies from “Sell” to “Hold,” while broader analyst sentiment remains “Hold,” with an average price target of $27.83.
• KMTS shares opened at $26.40 after rising 4.5%; the company recently reported a quarterly loss of $0.67 per share, missing estimates by $0.08, on revenue of $28.64 million.
• Insiders sold 211,877 shares worth approximately $4.9 million over the past 90 days, including sales by the CFO and another insider to cover tax obligations related to vested equity awards.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Several other research analysts have also recently issued reports on the company. Weiss Ratings cut Kestra Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, July 16th. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a "market perform" rating on the stock. BTIG Research lifted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $27.83.

Kestra Medical Technologies Trading Up 4.5%

NASDAQ:KMTS opened at $26.40 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies has a one year low of $14.30 and a one year high of $30.00. The company has a market cap of $1.55 billion, a PE ratio of -10.91 and a beta of 0.58. The firm has a 50-day moving average of $22.96 and a 200-day moving average of $22.57.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, equities research analysts expect that Kestra Medical Technologies will post -2.29 EPS for the current fiscal year.

Insider Activity at Kestra Medical Technologies

In related news, CFO Vaseem Mahboob sold 8,817 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37. Following the completion of the transaction, the chief financial officer owned 99,282 shares in the company, valued at approximately $2,244,766.02. This represents a 8.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy P. Moran sold 8,759 shares of Kestra Medical Technologies stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $198,040.99. Following the completion of the sale, the insider directly owned 68,725 shares in the company, valued at approximately $1,553,872.25. This represents a 11.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 211,877 shares of company stock valued at $4,922,844 in the last 90 days. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company's stock worth $115,878,000 after acquiring an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. lifted its holdings in Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock valued at $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. boosted its position in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company's stock worth $35,449,000 after purchasing an additional 179,885 shares during the period. Eventide Asset Management LLC increased its stake in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock worth $33,671,000 after purchasing an additional 65,288 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company's stock worth $25,221,000 after purchasing an additional 612,343 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source